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Polycystic ovary syndrome (PCOS) is the commonest endocrine abnormality in women
of reproductive age typically presenting with chronic oligo- or anovulation, clinical, or
biochemical hyperandrogenism and polycystic ovarian morphology (PCOM). Restoring
mono-ovulation is the ultimate goal of ovulation induction andmost women do respond to
ovulation inducing agents causing their Follicle-stimulating hormone (FSH) levels to rise.
Familial clustering and the results from twin studies strongly support an underlying genetic
basis for PCOS. Recent Genomewide association studies (GWAS) have identified several
genetic variants being genome wide significantly associated with PCOS. Amongst those
are variants in or near the Luteinizing hormone (LH) and FSH receptor genes as well
as a variant in the FSH-β gene. The aim of this review is to summarize the available
evidence as to whether single nucleotide polymorphisms are able to modify the PCOS
phenotype or whether they constitute a risk factor for the syndrome. Data on the
role of FSHR polymorphisms in PCOS are conflicting. It seems that in large Chinese
studies FSHR polymorphisms are not associated with either PCOS risk or with PCOS
treatment outcome. However, in large scale studies in Caucasians these polymorphisms
seem to influence the risk of having PCOS. Moreover, these studies also showed that
some polymorphisms might affect some clinical features of PCOS as well as treatment
outcome. Although most research has focussed on the role of FSHR polymorphisms
there seems to be also some evidence showing that single nucleotide polymorphisms
(SNPs) in the LHCG-Receptor as well as those in FSH-β gene might also alter the
phenotype of PCOS. In conclusion most studies confirm that FSHR polymorphisms do
alter the phenotype of PCOS in that they either alter the response to exogenous FSH or
hat they increase the risk of having PCOS.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is the commonest endocrine abnormality in women of
reproductive age, estimated to affect 5–20% of women in most populations (1). It is a heterogenous
syndrome and according to the Rotterdam Criteria, PCOS is recognized in women who have two of
three symptoms: chronic amenorrhea, clinical, or biochemical hyperandrogenism and the ovarian
morphology of polycystic ovarian morphology (PCOM) in ultrasound imaging, after other reasons
have been excluded (2). The syndrome is also associated with distressing cutaneous manifestations
of androgen excess such as hirsutism and acne (3).
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The typical biochemical features are elevated serum
concentrations of testosterone and luteinizing hormone
(LH), but PCOS is also associated with a characteristic metabolic
disturbance that includes insulin resistance, hyperinsulinaemia,
and abnormalities of energy expenditure. Crucially, PCOS is now
recognized as a major risk factor for the development of type 2
diabetes (T2D) and cardiovascular disease in later life. Women
with PCOS have a 3 to 7-fold increase in risk of T2D (3). At
least in part, this reflects the strong associations between PCOS
and obesity, with the latter a frequent concomitant, and likely
amplifier, of the PCOS state (4).
Finally, it represents the major cause of anovulatory infertility,
involving up to 20% of infertile couples. Restoring mono-
ovulation is the ultimate goal of ovulation induction strategies.
Typically these women do respond to ovulation inducing agents
causing their own endogenous follicle-stimulating hormone
(FSH) levels to rise and initiate ovulation or inducing the latter
by administering exogenous FSH to them (5).
GENETICS OF PCOS
PCOS clusters within families and having a first degree relative
suffering from PCOS conveys a 25% risk of either developing
the full blown clinical picture or having a 25% risk of sharing
characteristics of the syndrome amongst siblings to other siblings
(6, 7). Similar results were obtained in several twin studies
showing higher rates of concordance in PCOS characteristics
between monozygotic twin sisters compared to dizygotic twins
(8). Taken together these data strongly suggest a complex genetic
basis for PCOS.
Several studies have attempted to explain the high overall
prevalence of PCOS among women worldwide despite its
link to subfertility and thus constituting an evolutionary
paradox. Recently it has been shown that several genetic loci
associated with the disease differently modulate the reproductive
parameters of men and women. This observation suggests that
these genetic variants lead to opposite effects on reproductive
success in women and men. Intra-locus sexual conflict as a
cause of the persistence of PCOS supports the high prevalence
throughout evolution in humans (9).
To date, large numbers of genetic studies have identified
over 200 susceptibility genes that might be functionally related
to PCOS. However, the vast majority of these have not been
replicated in other studies (10). Because PCOS seems to be a
complex multigenic disease a more comprehensive, unbiased,
non-hypothesis driven approach seems to be more informative.
Hence high throughput genome association studies (GWAS)
should be performed in order to unravel the genetic background
of PCOS.
Recent GWAS have identified up to 18 genetic variants
being genome wide significantly associated with PCOS (11–
14) (Figure 1). Amongst those are variants in or near the
LH (LHCGR) and FSH receptor (FSHR) genes as well as
a variant in the FSH-β gene. Most of the identified genes
have been identified and replicated in Chinese, South-East
Asians as well as in Caucasian populations (15). Moreover,
Mendelian randomization analyses indicate causal roles in
PCOS etiology for higher body mass index (BMI), higher
insulin resistance, and lower serum sex hormone binding
globulin concentrations. Furthermore, genetic susceptibility to
later menopause is associated with higher PCOS risk and PCOS-
susceptibility alleles are associated with higher serum anti-
Müllerian hormone concentrations in girls (14). In a recent paper
the functional roles of strong PCOS candidate loci focusing on
FSHR, LHCGR, insulin receptor (INSR), and the DENND1A
gene were reviewed. The authors of this paper propose that
these candidates comprise a hierarchical signaling network by
which DENN domain containing 1A (DENND1A), LHCGR,
INSR, RAS oncogene family member 5B (RAB5B), adapter
proteins, and associated downstream signaling cascades converge
to regulate theca cell androgen biosynthesis (16).
FSHR POLYMORPHISMS
The FSHR gene is located on chromosome 2 p21-p16 and consists
of 10 exons and 9 introns. The first 9 exons encode for the
extracellular domain of the receptor, whereas exon 10 encodes
for the C-terminal end of the extracellular domain, the entire
transmembrane domain and the intracellular domain of the
FSHR. Exon 10 is fundamental for signal transduction, but it
is not necessary for ligand binding. Up till now around 1,800
SNPs of the FSHR gene have been reported in the National
Centre for Biotechnology Information (NCBI) SNP database
(http://www.ncbi.nlm.nih.gov). SNPs are located either in the
coding regions (exons, 8 SNPs), or within intronic regions of
exons. Only 1 SNP is located in the 5′ untranslated region
of the FSHR mRNA position−29 (ss2189241). Of the eight
SNPs within coding regions 7 are located in exon 10 at codon
positions 307, 329, 449, 524, 567, 665, and 680. Six of the
latter SNPs eventually result in amino acid substitution and
are therefore non-synonymous. The two best characterized
polymorphisms as far as their allele frequencies and ethnic
distribution is concerned are the Ala307Thr (rs6165) and the
Ser680Asn (rs6166). Both of these polymorphisms are linked to
each other during recombination in a way that they always occur
together (17).
Several studies aimed to correlate the FSHR polymorphism
and ovarian function. The polymorphism at position 680
harboring Serine residues at both alleles is associated with higher
endogenous FSH serum concentrations and a longer follicular
phase length. This suggest that this FSHR variant is less sensitive
to FSH. Indeed, women having the Ser/Ser variant needed more
exogenous FSH during their ovarian stimulation phase during
IVF treatment cycles. Moreover, Asn680Ser polymorphism was
not associated with premature ovarian failure (POI). Finally, in
women with PCOM the distribution of the two allelic variants
greatly varied amongst different studies (17–20).
FSH RECEPTOR POLYMORPHISMS AND
PCOS
FSHR Polymorphisms and PCOS
Susceptibility
The first study ever which screened the entire coding region
of FSHR gene for pathogenic mutations in 124 patients with
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FIGURE 1 | Manhattan plot showing results of meta-analysis for PCOS status, adjusting for age. The inverse log10 of the p value (−log10(p)) is plotted on the Y axis.
The green dashed line designates the minimum p value for genome-wide significance (<5.0 × 10−8). Genome wide significant loci are denoted with a label showing
the nearest gene to the index SNP at each locus. SNPs with p values <1.0 × 10−2 are not depicted.
PCOS and found no mutations in these patients. The two
well-known polymorphisms, Thr307Ala and Ser680Asn showed
similar distributions of the allelic variations and protein isoforms
in PCOS compared to 236 normal healthy control subjects. It
appears from this study that mutations in the coding regions
of FSHR gene are not a causative factor for PCOS in Chinese
Singapore women (21). Similarly, Fu and co-workers recruited
384 unrelated PCOS patients and 768 healthy individuals from
the Shaanxi province in the northern part of China. The
Ala307Thr and Ser680Asn polymorphisms were studied together
with clinical characteristics of the study subjects in a case-control
setting. The frequency of FSHR Ala307Thr and Ser680Asn
variants along with the haplotype were not significantly different
between the PCOS patients and the controls although the
Ser680 variants seemed to be associated with higher levels of
endogenous FSH and low estradiol levels. This study suggests
that the two variants of the FSHR gene are not a causative
factor of PCOS in Northern Chinese Han women (22). In
another study in Han Chinese women suffering either from
PCOS (n = 215) or being healthy controls (n = 205) recruited
from Shanxi Province in north China the Ala307Thr and
Ser680Asn polymorphisms of FSHR were not associated with
PCOS. However, the FSHR polymorphisms were related to
the endogenous serum concentrations of FSH and Prolactin.
No other PCOS-associated endocrine hormones as well as
clinical pregnancy rates in PCOS patients were recorded in
that study (23). Only one study in Chinese women revealed
a significant between FSHR polymorphisms and PCOS. In a
case-control sample using 60 PCOS patients and 92 healthy
controls all being unrelated Han Chinese from Shanghai the
haplotypes covering components Thr307Ala andAsn680Ser were
studied. These authors observed a significant association of both
polymorphisms and PCOS (24).
Ten case-control studies were included in the first meta-
analysis addressing the relationship between the commonest
FSHR polymorphisms and PCOS. This meta-analysis showed
no consistent association between either the Thr307Ala
polymorphism or the Asn680Ser polymorphism and
susceptibility to PCOS. Stratified analysis of ethnicities also
showed no association. The authors of this meta-analysis
suggested that the FSHR polymorphisms were not associated
with an increased risk of PCOS (25). In a second meta-analysis
data from 11 studies were analyzed. The pooled odds ratio
and 95% confidence interval were calculated using fixed- or
random-effect model based on heterogeneity test in 5 genotype
models analyses. This analysis showed that the Asn680Ser
polymorphism was significantly associated with the reduced
susceptibility to PCOS in a dominant model as well as in
recessive, homozygote comparison, and allele contrast models.
All Odds ratios were similar reducing the chance of having PCOS
with about 20%. However, no significant associations were found
between Thr307Ala and PCOS (26).
In a Korean study recruiting 235 PCOS patients and 128
control subjects, all within their reproductive age years, from
Seoul. The FSHR polymorphisms Ser680Asn and Ala307Thr
genotype frequencies were measured. They found that the
Ser680Asn of FSHR was significantly more often associated
with PCOS. In contrast the Ala307Thr variant was not at
all associated with PCOS. However, their haplotype analysis
revealed that both the Ser680Asn and Ala307Thr polymorphisms
did not constitute a risk factor for PCOS (27). In another
study genotyping was performed in 377 women with PCOS
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and 388 age-matched controls all from South Korean origin.
Findings of this study suggest a significant association between
FSHR gene polymorphisms Thr307Ala and the Asn680Ser allele
frequencies and PCOS. The homozygote variant genotype results
in significantly higher risk of PCOS (28). In a population of
522 Japanese women, the overall frequency of Asn/Asn, Asn/Ser,
and Ser/Ser was 41.0, 46.9, and 12.1%, respectively. In polycystic
ovary patients, the Asn/Ser population was significantly larger
when compared with the spontaneously ovulating group (29).
In a Pakistani study genomic results from 96 women with
PCOS were compared with those from 96 healthy controls from
the Punjab region in Pakistan. This study provides evidence
of statistically significant associations between susceptibility
to PCOS in Pakistani women and the gene polymorphisms
in FSHR, the LHHCG-Receptor, LH-β chain and both ER-
α and ER-β receptor genes (30). In another study in 386
Thai women with chronic anovulation either without (121
women) or with PCOS (133 women) using 132 known ovulatory
fertile women as controls no association between the FSHR
gene polymorphism at codons 307 and 680 and PCOS was
found (31).
The first published European study assessed the distribution
of the two most common FSHR polymorphisms in 148
normogonadotropic anovulatory infertile women and in 30
normo-ovulatory controls. Normogonadotropic anovulatory
infertile patients have a different FSH receptor genotype than
do normo-ovulatory controls (32). In another study in Dutch
women with PCOS FSHR variants were strongly associated with
the severity of clinical features of PCOS. The findings in a
discovery cohort of 240 women with PCOS were replicated
in another independent sample of 185 women suffering from
PCOS and showed that the Ser/Ser genotype was associated
with higher endogenous levels of FSH, LH and testosterone
(19, 20).
In a study in Turkish adolescent girls the possible association
between SNPs of the FSHR was studied. Samples from 44
adolescent girls with PCOS and 50 healthy controls were
compared. Polymorphic loci on the FSHR (A307T, N680S) genes
did not reveal any significant differences between cases and
controls. These data do not support an association between
SNPs of the FSHR and the susceptibility to PCOS in Turkish
adolescent girls (33). Another study in Caucasians included 294
premenopausal Caucasian patients with PCOS, and 78 women
with regular menorrhea and without hirsutism. In this study in
Polish women no differences in genotype and allele frequencies
of the Ser680Asn and Ala307Thr polymorphisms between the
case and the control groups. In addition, the two FSHR variants
in exon 10 did not increase the risk for PCOS in Polish
women (34).
To assess the cross-ethnic effect a meta-analysis of the Dutch
data (703 Dutch PCOS patients and 2,164 Dutch controls)
combined with results of previously published studies in PCOS
patients from China (n = 2,254) and the United States
(n = 2,618) has been performed. Overall, this study observed
for 12 of 17 genetic variants mapping to the Chinese PCOS loci
similar effect size and identical direction in PCOS patients from
Northern European ancestry, indicating a common genetic risk
profile for PCOS across populations. In this study two previously
identified GWAS FSHR polymorphisms, i.e., rs2268361 and
rs2349415 were significantly associated with PCOS (15). Another
study trying to replicate the Chinese GWAS findings in
Caucasians included 905 women with PCOS and 956 control
women. The strongest evidence for associationmapping to FSHR
was observed with rs1922476. Furthermore, markers with the
FSHR gene region were associated with FSH levels in women
with PCOS. Fine mapping of the chromosome 2p16.3 Chinese
PCOS susceptibility locus in a European ancestry cohort provides
evidence for association with two independent loci and PCOS.
The gene products of the FSHR gene are therefore likely to
be important in the etiology of PCOS, regardless of ethnicity
(35). An American study tried to replicate the FSHR variants
from the Chinese GWA studies in case-control examination
in a discovery cohort of 485 women with PCOS and in 407
controls from Boston. Replication was performed in women
from 884 PCOS cases and 311 controls from Greece and in
an additional cohort from Boston constituting 350 cases and
1,258 controls. One variant, rs2268361-T, in the intron of FSHR
was associated with PCOS and lower FSH levels (36). In an
effort to replicate the hits for the Chinese GWA studies 845
European subjects with PCOS and 845 controls were recruited
into this study. Variants in DENND1A, THADA, the FSHR,
and the INS-Receptor were associated with PCOS in Europeans.
The genetic risk score, generated for each subject based on the
total number of risk alleles, was associated with the diagnosis of
PCOS and remained associated even after exclusion of the four
variants individually associated with PCOS (37). Finally, in an
Arab case-control study, involving 203 women with PCOS, and
211 age- and ethnically-matched control women. Significantly
lower frequencies of a heterozygous FSHR variant (rs11692782)
genotype carriers were observed between women with PCOS and
controls (38). In summary most studies in Chinese and Thai
women did not substantiate an increased susceptibility for PCOS
based on FSHR polymorphisms. In contrast Studies in Korean
and Pakistani women did find an increased susceptibility for
PCOS based SNP’s in the FSHR. Results from meta-analysis are
contradictory whereas most studies in women from Caucasian
descent revealed a clear-cut increased susceptibility for PCOS
based on the FSHR genotype (Table 1).
FSHR Polymorphisms and Clinical
Features of PCOS
One study aimed to investigate whether the PCOS related
SNPs in the FSHR gene are associated with PCOM. The 447
unrelated Han Chinese PCOS from south China were grouped
into PCOM (n = 384) and non-PCOM (n = 63) women.
Significant differences were found in the allele distributions of the
GG genotype of rs2268361 between the PCOM and non-PCOM
groups while no significant differences were observed in the allele
distributions of the GG genotype of rs2349415. When rs2268361
was considered, there were statistically significant differences of
serum FSH, estradiol, and sex hormone binding globulin between
genotypes in the PCOMgroup. In case of the rs2349415 SNP, only
serum sex hormone binding globulin was statistically different
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TABLE 1 | Showing the effect different single nucleotide polymorphisms have on either the prevalence of PCOS or on different phenotypical features of the syndrome.
SNP Location Risk for PCOS Effect Ethnicity References
FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR)
FSHR rs6165
rs6166
Similar
Similar
Not reported
Not reported
Chinese (21)
FSHR rs6165
rs6166
Similar
Similar
No effect
Higher FSH and lower E2
Chinese (22)
FSHR rs6165
rs6166
Similar
Similar
Higher FSH and Prl
Higher FSH and Prl
Chinese (23)
FSHR rs6165
rs6166
Similar
Increased
Not reported
Not reported
Korean (27)
FSHR rs6165
rs6166
Increased
Increased
No effects on FSH, ovarian or metabolic markers
No effects on FSH, ovarian or metabolic markers
Korean (28)
FSHR rs6165
rs6166
Similar
Increased
No effect
Reduced FSH sensitivity
Lower E2 levels at OPU
Japanese (29)
FSHR rs6165
rs6166
Similar
Increased
Not reported
Not reported
Pakistani (30)
FSHR rs6165
rs6166
Similar
Similar
Not reported
Not reported
Thai (31)
FSHR rs6165
rs6166
Similar
Increased
No effect
Higher FSH levels
European (32)
FSHR rs6165
rs6166
Similar
Increased
No effect
Higher FSH levels
European (19)
FSHR rs6165
rs6166
Similar
Increased
No effect
Higher FSH and LH and Testosterone levels
European (39)
FSHR rs6165
rs6166
Similar
Increased
No effect
Higher FSH levels
European (20)
FSHR rs6165
rs6166
Similar
Similar
Not Reported
Not Reported
European (34)
FSHR rs6165
rs6166
Similar
Similar
No effect
No effect
Turkish (33)
FSHR rs7562215
rs10495960
rs2956355
rs7562879
rs13405728
Increased
Increased
Increased
Increased
Increased
Not reported
Not reported
Not reported
Not reported
Not reported
Caucasian (35)
FSHR rs2268361 Increased Lower FSH serum levels Caucasian (36)
FSHR rs11692782 Decreased Not reported Arab (38)
FSHR rs2268361
rs2349415
Not reported
Not reported
More PCOM
Different levels of FSH, E2 and SHBG
Different levels of SHBG
Chinese (40)
FSHR rs6165
rs6166
Similar
Similar
No differences in OI outcome
No differences in OI outcome
Caucasian (41)
FSHR rs6165
rs6166
Similar
Similar
No differences in OI outcome
No differences in OI outcome
Caucasian (42)
FSHR rs6165
rs6166
Increased
Similar
Higher ovarian responsiveness in OI
Similar ovarian responsiveness in OI
Caucasian (43)
FSHR rs6165
rs6166
Similar
Similar
Not reported
Not reported
Chinese
(Meta-analysis)
(25)
FSHR rs6165
rs6166
Similar
Decreased
Not reported
Not reported
Chinese
(Meta-analysis)
(26)
FSHR rs2268361 and
rs2349415
Increased
Increased
Not reported
Not reported
Caucasians and
Chinese
(Meta-analysis)
(15)
FOLLICLE-STIMULATING HORMONE ß CHAIN POLYMORPHISMS (FSHß)
FSHß T to C transition at
codon 76 (AccI)
Increased in Obese
PCOS women
Higher FSH levels in AccI cariers and No
deifferences in E2 and LH values
Chinese (44)
(Continued)
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TABLE 1 | Continued
SNP Location Risk for PCOS Effect Ethnicity References
FSHß rs11031010 Increased Higher LH serum levels Chinese (10)
LUTEINIZING HORMONE- AND HUMAN CHORIOGONADOTROPHIN-RECEPTOR (LHCG) POLYMORPHISMS
LHCGR rs7371084
rs4953616
Increased
Increased
Not reported Arab (38)
LHCGR rs13405728 Increased higher serum level of testosterone, triglycerides and
low-density lipoproteins
Chinese (45)
LHCGR rs13405728
rs7562879
Similar
Increased
Not reported
Not reported
Caucasians (35)
between genotypes in the PCOM group (40). Similar findings
were reported another study showing that the Ser/Ser genotype
had significantly higher basal level of serum FSH was observed
as compared with that in the Asn/Ser group (29). A study
trying to replicate the GWAS findings of the first two Chinese
studies in Caucasians found a similar relationship between FSHR
polymorphisms and lower FSH levels (36). Several Dutch studies
found similar relationships between the Ser/Ser FSHR variant
and higher basal endogenous FSH serum concentrations (19,
20, 39). In one study it was also reported that the Ser/Ser
variant was also associated with increased serum concentrations
of LH and testosterone (39). There is only limited information
available regarding the relationship between FSHR SNP’s and
the phenotype of PCOS. Some SNP’s are associated with the
PCOM whereas most data are showing a more strict relationship
between higher basal FSH serum levels and the least sensitive
FSHR (Table 1).
FSH RECEPTOR POLYMORPHISMS AND
TREATMENT OUTCOME IN PCOS
In order to determine whether an allelic variant of the FSHR gene
affects fertility parameters in women with PCOS a UK group
of investigators studied 93 women with PCOS and compared
those with 51 healthy controls. The allelic variant Thr307/Ser680
was found to be similarly prevalent in both study groups and
had no phenotype in terms of fertility parameters in women
with PCOS (41). In a study comparing 58 women with PCOS
and 80 healthy ethnically matched female controls there was
no evidence that the Asn680Ser FSHR genotypes were neither
associated with PCOS nor with the response to clomiphene
citrate (42).
In contrast in a population of 522 Japanese women the
NS genotype was significantly more prominent in women with
PCOS. In women with the SS genotype significantly higher
basal serum levels of FSH were observed as compared with the
NS group suggesting a lower sensitivity of this particular SNP.
Indeed, higher doses of the exogenous FSH was required to
achieve ovulation induction in the SS group. Moreover, after
hCG administration, estradiol levels at the time of ovum pick-
up were significantly lower in the SS group as compared to the
other allelic variants. In case the two receptor variants were over
expressed in 293T cell line no differences could be found in
either levels of FSH-stimulated cAMP production, PI turnover or
ligand-binding affinity. These results suggest some FSHR variants
might have clinical implications (29). Similar results have been
reported in a large Dutch case control cohort of women with
PCOS and healthy controls the Ser/Ser FSHR polymorphism was
associated with some clinical features such as FSH and LH serum
concentrations. Indeed, the Ser/Ser FSHR polymorphism seemed
to be less sensitive to endogenous FSH thereby leading to higher
serum concentrations of FSH. Surprisingly this variant was also
associated with higher serum LH and testosterone levels (32, 39).
In the same study the Dutch group revealed an association
with clomiphene citrate resistance during ovulation induction
treatment. A pooled analysis showed an 89% higher chance of
being CRA in homozygous carriers of the Ser/Ser FSHR variant.
Similarly, a lower chance of ongoing pregnancy [hazard ratio 0.51
(95% confidence interval 0.27–0.98)] was observed among these
patients during clomiphene citrate treatment in two independent
prospective cohorts (39). These data may be used to design a
treatment algorithm that is more efficacious and better tailored
to the individual patient (20).
Similar results were obtained from another Dutch group
retrospectively studying a cohort of 193 patients all diagnosed
with PCOS according to Rotterdam criteria and treated with
ovulation induction. Significantly more patients with Ser/Ser-
polymorphism were resistant to CC compared with the Asn/Ser
and Asn/Asn genotypes with an odds ratio for ovulation of
0.44. Patients with higher FSH levels, higher age and lower
BMI were significantly more likely to ovulate in univariate
analysis. In a multivariate logistic regression model, corrected
for age, BMI, mean ovarian, volume, hyperandrogenism,
and amenorrhea, only the FSHR genotype and basal FSH
serum levels were predictive for ovulation (19). An Italian
study compared 40 women with PCOS undergoing in-vitro
fertilization (IVF) with 66 normo-ovulatory women. That
study showed that the heterozygote FSH-R polymorphism
Ala307Thr was significantly more frequent in women with
PCOS compared to the normo-ovulatory subjects. Moreover,
the Ala307Thr SNP was more frequently associated with a
higher ovarian responsiveness to exogenous FSH (43). Although
smaller studies in Caucasian women did not reveal a clear-
cut relationship between FSHR polymorphisms and treatment
outcome the larger studies did reveal an increase in clomiphene
citrate resistance and the least sensitive FSHR (Ser680Ser
variant) (Table 1).
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OTHER GENETIC VARIANTS
GONADOTROPHIC REGULATION THAT
MIGHT BE ASSOCIATED WITH PCOS
FSH-β Gene Polymorphisms
In a cohort of 135 patients with PCOS and 105 normal control
subjects no missense mutations were found in the functional
units of the FSH-β gene in patients with PCOS. However, this
study identified a thymine-cytosine substitution in exon 3 (codon
76, TAT to TAC) that led to creation of a so called AccI digestion
site. The distribution pattern of this AccI polymorphism in the
patients was significantly different from that in the control group
since homozygous carriers were more often affected by PCOS.
Within the PCOS patient group homozygosity for Accl was
also associated with obesity. The latter finding correlated with
significantly higher androgen levels in the obese patients. Hence
the AccI polymorphism in FSHβ gene may be associated with
PCOS in somewomen, especially those with obesity (44). Ameta-
analysis of Chinese GWAS data showed that the allele frequency
difference of a SNP in the FSH-β gene (rs11031010) between
PCOS and controls was genome-wide significant. PCOS women
with AA and AC genotypes had a significantly higher LH serum
levels compared to women carrying the CC genotype. Hence,
variants in FSH-β gene are associated with PCOS and LH levels
in Han Chinese women. The FSH-β gene is thus likely to play
an important role in the etiology of PCOS, regardless of ethnicity
(10) (Table 1).
LHCG-Receptor Polymorphisms
In a retrospective case-control study, involving 203 women
with PCOS, and 211 age- and ethnically-matched control
women LHCGR genotyping was done by allelic exclusion
method. Significantly lower frequencies of heterozygous LHCGR
rs7371084 genotype carriers were seen between women with
PCOS vs. controls. Furthermore, an increased frequency of
heterozygous homozygous LHCGR rs4953616 genotype carriers
was detected between women with PCOS compared to control
women. The authors of this study observed a significant
increase of LHCG-Receptor variants (rs7371084, rs4953616)
SNP’s in women with PCOS (38). In a case control study
in Hui ethnic women from China 51 patients with PCOS
and 99 healthy women were involved. The frequencies of the
genotype and allele frequency of rs13405728 in LHCG-Receptor
gene were significantly different between the PCOS and the
control women. Moreover, PCOS cases with TT genotype of the
variant rs13405728 had higher serum level of total testosterone,
triglycerides, and low-density lipoproteins (LDL) than those with
the CC and CT genotypes. The authors concluded that the SNP
rs13405728 in the LHCG-Receptor gene was associated with
PCOS and some of its clinical features (45). An attempt to
replicate the Chinese SNP’s in an American cohort revealed that
the LHCG-Receptor variant (rs13405728) was not informative
in a white Americans from European descent. However, these
authors identified and genotyped three markers (rs35960650,
rs2956355, and rs7562879) within 5 kb of rs13405728. Of these,
rs7562879 was nominally associated with PCOS. The gene
products of the LHCRG-Receptor gene are therefore likely to be
important in the etiology of PCOS, regardless of ethnicity (35).
In Indian study involving 204 women with PCOS and
204 healthy, sex-, and age-matched controls. This study
demonstrated an association between LHCGR (rs2293275)
polymorphism and PCOS. Moreover, a significant association of
the GG allele with body-mass index, waist to hip ratio, insulin
resistance, LH, and LH/FSH ratio was demonstrated in PCOS
when compared with controls. Indeed this study also suggests
that LHCG-Receptor polymorphism are associated with PCOS
(46) (Table 1).
SUMMARY
Data from Chinese studies regarding the relationship between
FSHR polymorphisms and PCOS susceptibility are conflicting.
Although the majority of data do not substantiate such a
relationship (21–23) there is one report suggesting that FSHR
might play a role in genetic susceptibility to PCOS (24). Two
different meta-analysis revealed also contradictory results. The
first one suggested that the FSHR polymorphisms were not
associated with an increased risk of PCOS (25) whereas the last
one did reveal a decreased susceptibility to PCOS for Thr307Ala
variant carriers (26). Several Korean (27, 28) as well as Japanese
(29) and Pakistani studies (30) do substantiate the FSHR variants
as a susceptibility locus for PCOS. However, a study in Thai
women did not reveal such a relationship (31). It seems that
data from South-East Asia are different from those generated
in Chinese populations. In European women data are similarly
conflicting. Some Dutch studies revealed a straight on forward
association between FSHR gene polymorphisms and PCOS (19,
20, 39) whereas others did not substantiate such susceptibility
(17, 33, 34). Arab women carrying certain FSHR polymorphisms
seem to be more often suffering from PCOS too (38).
The most convincing evidence comes from larger replication
studies and a cross ethnic meta-analysis that revealed a strong
relationship between FSHR variants and PCOS susceptibility
(15, 35–37).
In conclusion along with these more convincing data
observations underpinning the association of FSHR
polymorphisms with clinical features indicating differences
in sensitivity of the different receptor genotypes. These receptor
variants might generate several phenotypes with differences in
basal serum FSH, LH, and testosterone concentrations. Some of
the data are also pointing in a direction that at least some of these
genetic variants have clinical implications in that they determine
individual sensitivity for exogenous FSH (19, 29, 32, 39, 42, 43).
The observation that treatment outcome is also partially
determined by FSHR polymorphisms is another clue that genetic
variants might play a role in the pathophysiology of PCOS
(19, 20, 29, 39, 42, 43).
In conclusion SNP’s in the FSHR gene causing genetic
variants in the FSHR on the one hand do determine the
susceptibility for PCOS and on the other had do also affect
the sensitivity of the receptor for exogenous FSH during
ovulation induction therapy. There is also limited evidence
showing that SNP’s in the LHCG-Receptor as well as those
in FSH-β gene might also determine a women’s susceptibility
for PCOS.
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